## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($198.42)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 6, Bearish: 3)

**1. Johnson & Johnson stock ticks up on lupus drug data as earnings loom**
- Source: ts2.tech | 20260106T181437 | Bullish | Relevance: 100%
- Johnson & Johnson (JNJ.N) shares rose by 0.5% after the company announced positive mid-stage data for its experimental lupus drug, nipocalimab, and plans for late-stage testing. This news spotlights J&J's drug pipeline ahead of its quarterly report and comes as the company also filed in Europe to expand a myeloma drug combo. Investors are now focused on upcoming earnings and the 2026 outlook, especially in light of ongoing talc litigation.

**2. Johnson & Johnson seeks EMA approval for teclistamabâ€“daratumumab combination**
- Source: PharmaTimes | 20260106T122816 | Bullish | Relevance: 100%
- Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) for an expanded indication of teclistamab in combination with subcutaneous daratumumab. This combination targets relapsed or refractory multiple myeloma patients and aims to offer off-the-shelf treatment options earlier in the treatment pathway. The application is supported by phase 3 MajesTEC-3 study results, which showed an 83.4 percent reduction in the risk of disease progression or death.

**3. J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark**
- Source: BioSpace | 20260105T132726 | Bearish | Relevance: 100%
- Johnson & Johnson has halted a Phase IIb trial for JNJ-95475939, a bispecific antibody for atopic dermatitis, after it failed to meet efficacy expectations in an interim analysis. J&J had paid Numab Therapeutics $1.25 billion upfront for the asset, which targeted IL-4 and IL-31. The company will now focus on other dermatology candidates, including assets acquired from Proteologix and a STAT6 program from Kaken Pharmaceutical.

**4. Johnson & Johnson (NYSE:JNJ) Trading Down 1.5% - Here's What Happened**
- Source: MarketBeat | 20260106T013411 | Somewhat-Bearish | Relevance: 100%
- Johnson & Johnson (NYSE: JNJ) shares experienced a 1.5% drop in mid-day trading on Monday, with the stock trading as low as $200.91 before settling around $204.32 on increased volume. The company has a "Moderate Buy" consensus rating from analysts, with an average target price of $212.62, and recently declared a quarterly dividend of $1.30 per share. This dip follows various analyst reports and an increase in trading volume, indicating active market interest.

**5. Legal Bay Settlement Funding Reports Johnson & Johnson Hit with Almost $1 Billion in Trial Damages During Fourth Quarter of 2025**
- Source: PR Newswire | 20260105T180832 | Bearish | Relevance: 100%
- Legal Bay Settlement Funding reports that Johnson & Johnson faced nearly $1 billion in trial damages during the fourth quarter of 2025 due to lawsuits related to its talc-based products. Recent verdicts include $40 million to two women in California for ovarian cancer and $966 million in October 2025 for mesothelioma. These substantial jury awards are increasing pressure on Johnson & Johnson to resolve thousands of outstanding talc lawsuits nationally.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-30 | Barclays | $217 | $197 | +10% |
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-30 | Barclays | main | Equal-Weight |
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +9%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 17.8x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (6 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $493.4B |
| Beta | 0.33 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 17.8 |
| Current P/E | 18.9 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.1% to -1.9% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). Underperforming sector by 3.6pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.87), momentum weakening. RSI neutral at 49. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.95% (CS: 20) | Neutral |
| RSI_14 | 49.0 | Neutral |
| MACD Histogram | -0.87 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $204.84
- **Stop Loss:** $198.42 (3.1% risk)
- **Target:** $217.68 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 205
- **Position Value:** $41,992.20
- **Portfolio %:** 41.99%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*